ANTIBODIES, METHODS AND KITS FOR DIAGNOSING AND TREATING MELANOMA

The present invention relates to a method of identifying if a subject is suitable for TCRL-based epitope directed therapy, comprising determining a level of epitope presentation on at least one cell of the subject using an antibody comprising an antigen recognition domain capable of binding to an MH...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	HAUS-COHEN, MAYA, DENKBERG, GALIT, REITER, YORAM, COHEN, CYRIL, KLECHEVSKY, EYNAV, MICHAELI, YAEL
Format:	Patent
Sprache:	eng ; fre ; ger
Schlagworte:	CHEMISTRY HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS TESTING
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention relates to a method of identifying if a subject is suitable for TCRL-based epitope directed therapy, comprising determining a level of epitope presentation on at least one cell of the subject using an antibody comprising an antigen recognition domain capable of binding to an MHC-I molecule being complexed with a peptide fragment of said antigen, wherein the antibody does not bind said MHC-I in the absence of said complexed peptide fragment of said antigen, and wherein the antibody does not bind said peptide fragment of said antigen in an absence of said MHC, wherein a level value higher than a predetermined threshold is indicative of an individual being suitable for TCRL-based epitope directed therapy. The present invention further relates to a method of identifying if a subject is suitable for CTL-based epitope directed therapy, comprising determining a level of epitope presentation on at least one cell of the subject using an antibody comprising an antigen recognition domain capable of binding to an MHC-I molecule being complexed with a peptide fragment of said antigen, wherein the antibody does not bind said MHC-I in the absence of said complexed peptide fragment of said antigen, and wherein the antibody does not bind said peptide fragment of said antigen in an absence of said MHC, wherein a level value lower than a predetermined threshold is indicative of an individual being suitable for CTL-based epitope directed therapy.